NovaBay Will Discuss i-LidCleanser At the Academy of Optometry 2014 Conference

By November 10, 2014

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, announced today that the company will be exhibiting its i-Lid™ Cleanser with Neutrox at Academy 2014 Denver, the annual meeting of the American Academy of Optometry in Denver, November 12-15.

During the meeting, NovaBay will be sponsoring two dinners. One will be on November 12th at the Denver Art Museum, where Dr. Art Epstein, Director of the Dry Eye – Ocular Surface Disease Center and Director of Clinical Research at Phoenix Eye Care, will describe how i-Lid Cleanser is part of a new paradigm for eye care.

The other dinner will be at the 1515 Restaurant on November 13, where Dr. Christine W. Sindt, Director, Contact Lens Service, and Clinical Associate Professor of Ophthalmology and Visual Sciences at University of Iowa’s Carver College of Medicine, will present successful case studies of the use of i-Lid Cleanser.

As both Drs. Epstein and Sindt will explain, i-Lid Cleanser is the only eye care product to contain Neutrox—NovaBay’s proprietary and patented pure hypochlorous acid (HOCl) solution. Labs tests show that Neutrox replicates a naturally occurring substance released by white blood cells to fight microbial invaders, has potent antimicrobial activity, and yet is non-toxic to mammalian cells. It also neutralizes bacterial toxins, and has been cleared by the Food and Drug Administration to clean skin and wounds.

As a result of its properties, i-Lid Cleanser is ideally suited for the treatment of common eye conditions, such as blepharitis, where Staphylococci bacteria grow on eyelids, causing swelling, redness, inflammation, irritation and a crusty build-up. Patients who’ve had blepharitis for years—along with their doctors—report that i-Lid has finally brought relief from the often-painful condition. Many eye doctors are also now using i-Lid Cleanser routinely in preparation for cataract surgery and other types of surgery, and to treat dry eye syndrome. Because Neutrox is not a traditional antibiotic or steroid, there are no risks of bacterial resistance or side effects.

In addition to the presentations by Drs. Epstein and Sindt, NovaBay will be exhibiting i-Lid Cleanser at its booth (Booth #1121) during the entire conference.

“Conferences like Academy 2014 provide wonderful opportunities to talk about the benefits of Neutrox and i-Lid Cleanser,” said Dr. Ron Najafi, Chairman and CEO of NovaBay. “As eye care professionals continue to see the results from using i-Lid Cleanser, we believe they will realize how much it can improve the care of many common eye conditions.”

For NovaBay i-Lid Cleanser purchasing information, please contact:
Email us
Call us: 1-800-890-0329

Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website

For investor information, please contact:
Thomas J. Paulson  
Chief Financial Officer
Contact Thomas Paulson

For additional video testimonials and webinars please visit:



Forward-looking Statements

This release contains forward-looking statements and opinions regarding the commercial potential of i-Lid Cleanser, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs.  The words “believe,” “will,” “estimated,” “potential,” and “expectation,” are intended to identify the forward-looking statements.  Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the actual effectiveness of NovaBay products and unexpected adverse side effects or inadequate therapeutic efficacy of i-Lid Cleanser, and the risk that potential customers will not perceive the benefits of i-Lid Cleanser to be the same as NovaBay believes. Other risks relating to NovaBay and its products, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.